WEAVER GREGORY L 4
4 · Altimmune, Inc. · Filed Feb 27, 2026
Research Summary
AI-generated summary of this filing
Altimmune (ALT) CFO Gregory Weaver Receives Equity Awards
What Happened
Gregory L. Weaver, Chief Financial Officer of Altimmune, Inc. (ALT), received equity awards on February 26, 2026 consisting of 259,000 derivative shares (stock option award) and 111,000 Restricted Stock Units (RSUs). Both grants show an acquisition price of $0.00 (typical for compensation awards); no cash changed hands. The awards vest over four years under the schedules described in the filing.
Key Details
- Transaction date: 2026-02-26; Form 4 filed 2026-02-27 (timely filing).
- Awards: 259,000 option-based derivative shares (granted at $0.00) and 111,000 RSUs (each RSU converts to one share when vested).
- Vesting (options): 25% vest on Feb 26, 2027; remaining 75% vests in equal monthly installments over the following 36 months, subject to continued service.
- Vesting (RSUs): 25% vest on Feb 26, 2027; remaining RSUs vest in equal annual installments over the next three years; RSUs have no expiration date.
- Shares owned after transaction: not disclosed in the filing.
- No mention of tax withholding, 10b5-1 plan, or immediate sale; these are compensation grants, not open-market purchases or sales.
Context
These awards are compensation-related grants to an executive. Options are rights to acquire shares in the future if and when exercised; RSUs convert to actual shares upon vesting. Such grants are common for executive retention and do not by themselves indicate immediate buying or selling of shares.
Insider Transaction Report
- Award
Stock Options (option to buy)
[F1]2026-02-26+259,000→ 259,000 totalExercise: $4.46Exp: 2036-02-26→ Common Stock, par value $0.0001 (259,000 underlying) - Award
Restricted Stock Units
[F2][F3]2026-02-26+111,000→ 111,000 total→ Common Stock, par value $0.0001 (111,000 underlying)
Footnotes (3)
- [F1]The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on February 26, 2027, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date.
- [F2]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
- [F3]The RSUs become vested over four (4) years with 25% of the shares vesting February 26, 2027, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.